Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CPRX

+ Watchlist+ Portfolio

Catalyst Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
—
52-Week Range
—
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Dividend Yield
—
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
—
Gross Margin
—
Operating Margin
—
Profit Margin
—
Current Ratio
—
Debt/Equity
—
Total Debt
—
Free Cash Flow
—
Revenue Growth
—
Earnings Growth
—
Enterprise Value
—

Market Snapshot

About

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Coral Gables, Florida, focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. The company's lead product, Firdapse (amifampridine phosphate), is approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Catalyst is also developing treatments for other rare conditions including congenital myasthenic syndromes and spinal muscular atrophy. The company specializes in identifying underserved patient populations and bringing therapeutic solutions to market for these rare disease communities.